Black Hawk Acquisition Corporation Rights

Vesicor Therapeutics, a biotech company developing p53-based cancer therapeutics, announced the appointment of Michael Tolentino, M.D. as Chief Executive Officer effective March 17, 2026. Tolentino, a serial entrepreneur with over 20 years of biotech experience, succeeds founder Luo Feng who transitions to Chief Scientific Officer. The leadership...

Vesicor Therapeutics, a biotechnology company focused on p53-based cancer therapeutics, has entered into a business combination agreement with Black Hawk Acquisition Corporation to create a public company advancing its drug candidate.